About the Authors
- Anna Rydén
-
* E-mail: anna.ryden@astrazeneca.com
Affiliation AstraZeneca, Mölndal, Sweden
- Elisabeth Sörstadius
-
Affiliation AstraZeneca, Mölndal, Sweden
- Klas Bergenheim
-
Affiliation AstraZeneca, Mölndal, Sweden
- Alexandru Romanovschi
-
Affiliation AstraZeneca, Mississauga, Canada
- Fredrik Thorén
-
Affiliation AstraZeneca, Mölndal, Sweden
- Edward A. Witt
-
Affiliation Kantar Health, Princeton, NJ, United States of America
- Catarina Sternhufvud
-
Affiliation AstraZeneca, Mölndal, Sweden
Competing Interests
The authors received funding from AstraZeneca, a commercial company, for this study, both in funding and in salary. Author EW received funding from Kantar Health, a commercial company, in the form of salary. Kantar Health was paid for EW’s consultation on this study. There are no patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: A. Rydén ES KB A. Romanovschi FT EW CS. Formal analysis: EW. Methodology: A. Rydén ES KB A. Romanovschi FT EW CS. Writing – original draft: A. Rydén EW. Writing – review & editing: A.Rydén ES KB A. Romanovschi FT EW CS.